Evolus Q3 revenue +27% to $33.9M; reiterates FY2022 guidance at top end

Evolus, Inc.

2022-Q3 EPS reported -$1.09 revenue$104,970,000

Revenue $33.9M (+27% YoY); deferred $3.5M incremental due to 'Switch Your Tox' campaign, understating growth.
FY2022 revenue guidance top end $143-150M; non-GAAP opex guidance lowered to lower half of $135-140M.
Cash $65.6M; expects to fund through breakeven; operating cash use $17.1M, $3.8M less than Q2.
Added 650 new accounts (total >8,800); Evolus Rewards ~450,000 members with record 100,000 redemptions.
Launched Great Britain ops for Nuceiva; Phase II extra-strength Jeuveau enrollment completed.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolus, Inc. reported full-year 2022 results: revenue $143 to $150 million. Guidance reaffirmed.

Period: full-year 2022
Revenue: $143 to $150 million
Guidance: reaffirmed
Result: guidance update

Exact text from the filing

the company continues to project full-year 2022 sales at the top end of its guidance range of $143 to $150 million, which includes a minimal contribution from international markets.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Evolus, Inc. reported third quarter ended September 30, 2022 results: revenue $33.9 million.

Period: third quarter ended September 30, 2022
Revenue: $33.9 million
Result: reported results

Exact text from the filing

Total net revenues for the third quarter of 2022 increased 27% to $33.9 million from $26.7 million in the third quarter of 2021 driven almost entirely by higher volumes of Jeuveau

View on SEC.gov

Browse all earnings releases →

Evolus, Inc. filing history →

Source: SEC EDGAR

accession 0001570562-22-000141

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.